Main menu

RNA liquid biopsy via nanopore sequencing for novel biomarker discovery and cancer early detection


Using Oxford Nanopore sequencing, Peddu and Hill et al. profiled full-length cell-free RNA from blood plasma and uncovered over 270,000 novel transcripts — far beyond the reach of short-read methods. Utilising machine learning models, the team classified early stage oesophageal cancer and precancer with 100% sensitivity and specificity, demonstrating the potential of nanopore sequencing as a non-invasive tool for early cancer detection and monitoring.

'Here we show that nanopore sequencing can be leveraged to comprehensively characterize the vast, unannotated cell-free RNA transcriptome across healthy, precancerous, and cancerous disease states'

Peddu and Hill et al. 2025

Sample type: cell-free RNA from blood plasma

Kit: Ligation Sequencing Kit, Native Barcoding Kit

Authors: Vikas Peddu, Alexander Hill, Sree Lakshmi Velandi Maroli, Connor Mattingly, Joshua M.V. Gardner, Karen H. Miga, Rebecca C. Fitzgerald, Daniel H. Kim

入門

MinION Starter Packを購入 ナノポア製品の販売 シークエンスサービスプロバイダー グローバルディストリビューター

ナノポア技術

ナノポアの最新ニュースを購読 リソースと発表文献 Nanopore Communityとは

Oxford Nanoporeについて

ニュース 会社沿革 持続可能性 経営陣 メディアリソース & お問い合わせ先 投資家向け パートナー向け Oxford Nanopore社で働く 現在の募集状況 営業上の情報 BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Japanese flag